Oncternal Therapeutics (ONCT)

Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q2 2019 Results - Earnings Call Transcr
Aug. 11, 2019 | Price: Free! | Source: Seeking Alpha

GTx (GTXI) Q4 2015 Results - Earnings Call Webcast
March 3, 2016 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q4 2015 Results - Earnings Call Transcript
March 3, 2016 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q3 2015 Results - Earnings Call Transcript
Oct. 29, 2015 | Price: Free! | Source: Seeking Alpha

GTx (GTXI) Q3 2015 Results - Earnings Call Webcast
Oct. 29, 2015 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q2 2015 Results - Earnings Call Transcript
Aug. 6, 2015 | Price: Free! | Source: Seeking Alpha

GTx (GTXI) Q2 2015 Results - Earnings Call Webcast
Aug. 6, 2015 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q1 2015 Results - Earnings Call Transcript
May 8, 2015 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q4 2014 Results - Earnings Call Transcript
March 4, 2015 | Price: Free! | Source: Seeking Alpha

GTx (GTXI) Q3 2014 Results - Earnings Call Webcast
Nov. 10, 2014 | Price: Free! | Source: Seeking Alpha

GTx's (GTXI) CEO Marc Hanover on Q3 2014 Results - Earnings Call Transcript
Nov. 10, 2014 | Price: Free! | Source: Seeking Alpha

GTx's CEO Discusses Q4 2013 Results - Earnings Call Transcript
March 4, 2014 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q3 2013 Earnings Conference Call Transcript
Nov. 12, 2013 | Price: $106.00 | Source: Thomson

GTx, Inc. Discusses Q2 2013 Results (Webcast)
Nov. 12, 2013 | Price: Free! | Source: Seeking Alpha

GTx's CEO Discusses Q3 2013 Results - Earnings Call Transcript
Nov. 12, 2013 | Price: Free! | Source: Seeking Alpha

GTx POWER Trials Results Conference Call Transcript
Aug. 19, 2013 | Price: $106.00 | Source: Thomson

GTx's CEO Presents at GTx POWER Trials Results Conference (Transcript)
Aug. 19, 2013 | Price: Free! | Source: Seeking Alpha

GTx, Inc. - Business Update Call Transcript
Aug. 19, 2013 | Price: Free! | Source: Earnings Impact

GTx, Inc. Q1 2013 Earnings Conference Call Transcript
May 3, 2013 | Price: $106.00 | Source: Thomson

GTx Inc.'s CEO Discusses Q1 2013 Results - Earnings Call Transcript
May 3, 2013 | Price: Free! | Source: Seeking Alpha

GTx's Management Presents at Citi Global Healthcare - Transcript
Feb. 25, 2013 | Price: Free! | Source: Seeking Alpha

GTx's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Feb. 21, 2013 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q4 2012 Earnings Conference Call Transcript
Feb. 21, 2013 | Price: $106.00 | Source: Thomson

GTx, Inc. Analyst Day Transcript
Feb. 15, 2013 | Price: $106.00 | Source: Thomson

GTx's CEO Hosts Analyst Day Conference (Transcript)
Feb. 15, 2013 | Price: Free! | Source: Seeking Alpha

GTX's CEO Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
Nov. 13, 2012 | Price: Free! | Source: Seeking Alpha

GTx Incorporated's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Nov. 8, 2012 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q3 2012 Earnings Conference Call Transcript
Nov. 8, 2012 | Price: $106.00 | Source: Thomson

GTx's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Aug. 8, 2012 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q2 2012 Earnings Conference Call Transcript
Aug. 8, 2012 | Price: $54.00 | Source: Thomson

GTx, Inc. Q1 2012 Earnings Conference Call Transcript
May 8, 2012 | Price: $54.00 | Source: Thomson

GTx, Inc. Q4 2011 Earnings Conference Call Transcript
Feb. 21, 2012 | Price: $54.00 | Source: Thomson

GTx Inc Q4 2008 Earnings Call Transcript
Feb. 17, 2009 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q3 2008 Earnings Call Transcript
Nov. 19, 2008 | Price: Free! | Source: Seeking Alpha

GTx, Inc. Q2 2008 Earnings Call Transcript
Sept. 8, 2008 | Price: Free! | Source: Seeking Alpha

GTx Inc. Q1 2008 Earnings Call Transcript
May 12, 2008 | Price: Free! | Source: Seeking Alpha

GTx Q4 2007 Earnings Call Transcript
Feb. 19, 2008 | Price: Free! | Source: Seeking Alpha

Recent filings

Current report, items 7.01, 8.01, and 9.01 - Oct. 3, 2019

Oncternal Therapeutics's Chief Executive Officer just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics's Chief Financial Officer just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics's Legal Counsel just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics director just declared 0 options - Sept. 16, 2019

Oncternal Therapeutics's Chief Scientific Officer just declared ownership of no shares of Oncternal Therapeutics - Sept. 9, 2019

Oncternal Therapeutics's Chief Business Officer just declared 0 options - Sept. 9, 2019

Oncternal Therapeutics's Chief Business Officer just declared ownership of no shares of Oncternal Therapeutics - Sept. 9, 2019

Oncternal Therapeutics's Chief Scientific Officer just declared 0 options - Sept. 9, 2019

Oncternal Therapeutics's Chief Medical Officer just declared 0 options - Aug. 28, 2019

Oncternal Therapeutics's Chief Medical Officer just declared ownership of no shares of Oncternal Therapeutics - Aug. 28, 2019

Securities to be offered to employees in employee benefit plans - Aug. 15, 2019

Oncternal Therapeutics Just Filed Its Quarterly Report: Net Loss Per Share B... - Aug. 9, 2019

Oncternal: Index To Unaudited Interim Condensed Consolidated Financial Statements Condensed Financial Statements Condensed Consolidated Balance Sheets - Aug. 9, 2019

Oncternal Reports Second Quarter 2019 Financial Results And Provides Business Update - Aug. 8, 2019

Joseph R. Hyde, III just provided an update on activist position in Oncternal Therapeutics - Aug. 1, 2019

Changes in Registrants Certifying - June 20, 2019

President of Oncternal Therapeutics was just granted 42,196 options - June 20, 2019

Shanghai Pharmaceuticals Holding Co., Ltd. just provided an update on activist position in GTx - June 17, 2019

GTx's Chief Financial Officer just picked up 48,988 shares - June 11, 2019

Major owner of GTx just picked up 2,495,114 shares - June 11, 2019

GTx director just picked up 26,174 shares - June 11, 2019

GTx director just picked up 14,677 shares - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

President of GTx just picked up 277,868 shares - June 11, 2019

GTx's General Counsel just declared ownership of no shares of GTx - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

Major owner of GTx just declared ownership of no shares of GTx - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

GTx director just declared ownership of no shares of GTx - June 11, 2019

President of GTx just declared ownership of no shares of GTx - June 11, 2019

GTx's General Counsel just picked up 9,299 shares - June 11, 2019

GTx director just picked up 717,752 shares - June 11, 2019

GTx's Chief Financial Officer just declared ownership of no shares of GTx - June 11, 2019

Oncternal Therapeutics Completes Reverse Merger With Gtx, Inc - June 10, 2019

Submission of Matters to a Vote of Security - June 5, 2019

Prospectuses and communications, business combinations - June 3, 2019

Important information concerning the Merger and the transactions contemplated by the Merger Agreement is set forth in the Joint Proxy - May 24, 2019

Prospectuses and communications, business combinations - May 24, 2019

Prospectuses and communications, business combinations - May 16, 2019

GTx Just Filed Its Quarterly Report: 4.   Basic and Di... - May 10, 2019

GTx Just Received a Notice of Effectiveness - May 7, 2019

Registration of securities, business combinations - May 6, 2019

Entry into a Material Definitive - April 30, 2019

Prospectuses and communications, business combinations - April 30, 2019

GTx: Documents Incorporated By Reference         None. EXPLANATORY NOTE - April 30, 2019

Registration of securities, business combinations - April 8, 2019

GTx Just Filed Its Annual Report:   Basic and Dil... - March 18, 2019

Prospectuses and communications, business combinations - March 7, 2019

Prospectuses and communications, business combinations - March 7, 2019

Gtx And Oncternal Therapeutics Enter Into Definitive Merger Agreement To Create Nasdaq-Listed Clinical-Stage Company Developing A Diverse Pipeline Of Novel Cancer Therapies - March 7, 2019

Mark N. Lampert just issued a filing suggesting it has sold all of its GTx - Feb. 14, 2019

Major owner of GTx just picked up 18,169 shares - Jan. 3, 2019

Gtx Reports Third Quarter 2018 Financial Results And Provides Corporate Update - Oct. 22, 2018

GTx director just picked up 8,334 shares - Oct. 2, 2018

GTx director just picked up 8,917 shares - Oct. 2, 2018

Major owner of GTx just picked up 10,417 shares - Oct. 2, 2018

Gtx Announces Top-Line Results From Placebo-Controlled Astrid Trial Of Enobosarm In Women With Stress Urinary Incontinence - Sept. 21, 2018

Gtx Provides Corporate Update And Reports Second Quarter 2018 Financial Results - Aug. 14, 2018

VP of GTx just disposed of 4,063 shares - July 17, 2018

VP of GTx just picked up 35 shares - July 17, 2018

Major owner of GTx just picked up 1,011 shares - July 3, 2018

GTx director just picked up 865 shares - July 3, 2018

GTx director just picked up 809 shares - July 3, 2018

GTx's Executive Chairman just picked up 5,000 shares - June 26, 2018

Perceptive Life Sciences Master Fund, Ltd. just provided an update on share ownership of GTx - May 29, 2018

GTx Just Filed Its Quarterly Report:   3.Basic and D... - May 15, 2018

Gtx Provides Corporate Update And Reports First Quarter 2018 Financial Results - May 15, 2018

Gtx Announces Early Completion Of Patient Enrollment In The Astrid Trial, A Phase 2 Clinical Trial Of Enobosarm In Stress Urinary Incontinence - April 9, 2018

GTx director just picked up 766 shares - April 3, 2018

Major owner of GTx just picked up 895 shares - April 3, 2018

GTx director just picked up 716 shares - April 3, 2018

GTx releases salary data. CEO sees compensation rise 16% - March 23, 2018

Securities to be offered to employees in employee benefit plans - March 16, 2018

GTx Just Filed Its Annual Report: Basic and Diluted... - March 13, 2018

Gtx Provides Corporate Update And Reports Fourth Quarter And Full Year 2017 Financial Results - March 12, 2018

Gtx Announced New Data Demonstrating Enobosarm’S Potential To Treat Stress Urinary Incontinence At Sufu 2018 - March 5, 2018

Joe Lewis just provided an update on share ownership of GTx - Feb. 20, 2018

Mark N. Lampert just provided an update on share ownership of GTx - Feb. 14, 2018

Entry into a Material Definitive - Feb. 9, 2018

GTx just filed a prospectus, suggesting it plans to soon issue some securities - Feb. 9, 2018

GTx's Prin Fin. & Acct. Officer just disposed of 3,090 shares - Jan. 9, 2018

VP of GTx just disposed of 4,965 shares - Jan. 9, 2018

GTx's Chief Executive Officer just disposed of 7,309 shares - Jan. 9, 2018

GTx Just Received a Notice of Effectiveness - Jan. 5, 2018

Major owner of GTx just picked up 1,364 shares - Jan. 4, 2018

GTx director just picked up 1,091 shares - Jan. 4, 2018

GTx director just picked up 1,168 shares - Jan. 4, 2018

GTx's Prin Fin. & Acct. Officer just disposed of 2,704 shares - Jan. 3, 2018

GTx's Chief Executive Officer just disposed of 6,397 shares - Jan. 3, 2018

VP of GTx just disposed of 4,345 shares - Jan. 3, 2018

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. HYDE JOSEPH R III 57,046,500 N/A April 2, 2015
2. Pyramid Peak Foundation 55,078,934 N/A April 2, 2015
3. Jack W. Schuler 12,246,208 N/A Nov. 3, 2015
4. Walter Rotchild 7,750,213 N/A Dec. 31, 2015
5. Formanek Investment Trust 7,400,000 N/A April 2, 2015
6. BlackRock Institutional Trust Company, N.A. 152,872 N/A Dec. 31, 2016
7. Aureus Asset Management, LLC 70,211 0.1 June 30, 2019
8. VANGUARD GROUP INC 31,782 N/A June 30, 2019
9. State Street Corp 26,998 N/A June 30, 2019
10. J.P. Turner & Co Capital Mnagement, LLC 21,300 N/A June 30, 2015
11. GEODE CAPITAL MANAGEMENT, LLC 20,180 N/A June 30, 2019
12. NORTHERN TRUST CORP 18,705 N/A March 31, 2018
13. BlackRock Advisors LLC 17,845 N/A Sept. 30, 2016
14. BlackRock Fund Advisors 9,421 N/A Sept. 30, 2016
15. North Star Investment Management Corp. 4,900 N/A Sept. 30, 2019
16. MEEDER ASSET MANAGEMENT INC 4,644 N/A Sept. 30, 2019
17. JPMORGAN CHASE & CO 4,113 N/A Sept. 30, 2017
18. Tower Research Capital LLC (TRC) 1,156 N/A June 30, 2019
19. Proficio Capital Partners LLC 652 N/A June 30, 2019
20. MORGAN STANLEY 359 N/A Dec. 31, 2016
21. DELTA ASSET MANAGEMENT LLC/TN 175 N/A June 30, 2019
22. BANK OF AMERICA CORP /DE/ 143 N/A Sept. 30, 2017
23. Legal & General Group Plc 97 N/A June 30, 2019
24. MORGAN STANLEY 81 N/A Sept. 30, 2017
25. CITIGROUP INC 80 N/A Sept. 30, 2017
26. MetLife Securities, Inc 60 N/A Dec. 31, 2016
27. BANK OF MONTREAL /CAN/ 33 N/A June 30, 2018

Oncternal Therapeutics (ONCT)

140
 


Feedback